^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BiCKI IL-7

    i
    Other names: BiCKI IL-7, OSE-279/IL-7, anti-PD-1 antibody fused with IL-7 interleukin, bifunctional anti-PD1/IL-7
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim, OSE Immunotherapeutics
    Drug class:
    PD1 inhibitor, IL-7 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    [VIRTUAL] Optimized antagonist anti-PD-1/IL-7 bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity (AACR 2021)
    Taken together, our data validate the therapeutic potential of providing IL-7 signal to strengthen PD1 therapy and prevent immunoresistance by sustaining T cell response and overcoming Treg suppression. The bispecific BiCKI®IL-7 mutein can preferentially deliver and activate IL-7 into PD1+ tumor-specific T cells limiting the risk of I-O/I-O immunotoxicity.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • IL7R (Interleukin 7 Receptor) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    CD8 expression
    |
    BiCKI IL-7